Scientific, political pressures colliding at FDA, delaying rare disease treatment for patients who have few or no options, experts said at CNBC Cures Summit.
Experimental therapies treating rare diseases have always faced a challenging road to reaching the people who need them. While the Food and Drug Administration has said it is moving ahead with new pr… [+7855 chars]
